1-2 of 2
Betty Prine
Close
Sort by
Journal Articles

Safety, Efficacy, and PK of the BCL2 Inhibitor Venetoclax in Combination with Chemotherapy in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia: Phase 1 Study

Seth E Karol, MD, Todd M Cooper, DO, Henrique Bittencourt, Lia Gore, MD, Maureen M O'Brien, MD, Christopher Fraser, MD, Marion Gambart, MD, Gunnar Cario, MD PhD, Christian Michel Zwaan, MD PhD, Jean-Pierre Bourquin, MD PhD, Mignon L. Loh, MD, Hubert Caron, MD PhD, Betty Prine, Ahmed Hamed Salem, PhD FCP, Kristina Unnebrink, Bo Tong, PhD, Tammy Palenski, PhD, Andrew E. Place, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2649.
https://doi.org/10.1182/blood-2019-129805
Published: 2019
Journal Articles

Deep and Durable Responses Following Venetoclax (ABT-199 / GDC-0199) Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results from a Phase 1b Study

Shuo Ma, MD, Danielle M. Brander, MD, John F. Seymour, MBBS, PhD, Thomas J. Kipps, MD PhD, Jacqueline C. Barrientos, MD, Matthew S. Davids, MD, Mary Ann Anderson, MBBS, Michael Y. Choi, MD, Constantine S. Tam, MBBS, Tanita Mason-Bright, Betty Prine, Wijith Munasinghe, PhD, Ming Zhu, PhD, Su Young Kim, MD, Rod A. Humerickhouse, MD PhD, Andrew W. Roberts, MBBS, PhD
Journal: Blood
Blood (2015) 126 (23): 830.
https://doi.org/10.1182/blood.V126.23.830.830
Published: 2015